Zobrazeno 1 - 10
of 43
pro vyhledávání: '"Stephen Zamora"'
Autor:
Mark E. Robson, Betty Ann Caravella, Mario E. Lacouture, Helen Won, Richard B. Lanman, M. Scaltriti, Neil Vasan, David B. Solit, Payal D. Shah, Aimee Cowan, Maura N. Dickler, Shanu Modi, Ronglai Shen, Elizabeth A. Comen, Weiyi Toy, Bob T. Li, Anne M. Covey, Komal Jhaveri, Sujata Patil, Jorge S. Reis-Filho, Rebecca J. Nagy, Pier Selenica, Pedram Razavi, Michael F. Berger, Stephen Zamora, Larry Norton, Mary Ellen Moynahan, Justin I. Odegaard, David N Brown, Clifford A. Hudis, Edi Brogi, Sarat Chandarlapaty, Andy Singh
Publikováno v:
Nature Cancer. 1:382-393
Alpelisib is a selective inhibitor of PI3Kα, shown to improve outcomes for PIK3CA mutant, hormone receptor positive (HR+) metastatic breast cancers (MBC) when combined with antiestrogen therapy. To uncover mechanisms of resistance, we conducted a de
Autor:
Pedram, Razavi, Maura N, Dickler, Payal D, Shah, Weiyi, Toy, David N, Brown, Helen H, Won, Bob T, Li, Ronglai, Shen, Neil, Vasan, Shanu, Modi, Komal, Jhaveri, Betty Ann, Caravella, Sujata, Patil, Pier, Selenica, Stephen, Zamora, Aimee M, Cowan, Elizabeth, Comen, Andy, Singh, Anne, Covey, Michael F, Berger, Clifford A, Hudis, Larry, Norton, Rebecca J, Nagy, Justin I, Odegaard, Richard B, Lanman, David B, Solit, Mark E, Robson, Mario E, Lacouture, Edi, Brogi, Jorge S, Reis-Filho, Mary Ellen, Moynahan, Maurizio, Scaltriti, Sarat, Chandarlapaty
Publikováno v:
Nat Cancer
Alpelisib is a selective inhibitor of PI3Kα, shown to improve outcomes for PIK3CA mutant, hormone receptor positive (HR+) metastatic breast cancers (MBC) when combined with antiestrogen therapy. To uncover mechanisms of resistance, we conducted a de
Autor:
Monica Fornier, Shanu Modi, Chau T. Dang, Theresa Gilewski, Sujata Patil, Stephen Zamora, Patrick G. Morris, Andrew D. Seidman, Clifford A. Hudis, Jacqueline Bromberg, Gabriella D'Andrea, Larry Norton, Maura N. Dickler, Selene Rota, Nancy Sklarin, Karen Cadoo
Publikováno v:
Clinical Breast Cancer. 18:387-394
Background Overexpression and activation of tyrosine kinase Src has been linked to breast carcinogenesis and bone metastases. We showed the feasibility of combining the SRC inhibitor dasatinib with weekly paclitaxel in patients with metastatic breast
Autor:
Akshay Swaminathan, Michael A Repucci, David C. Fajgenbaum, Mark D Hannan, Abigail Orlando, Xiaoliang Wang, Suganya Sridharma, Daniel Sepler, Barry Leybovich, Jonathan Kelly, Stephen Zamora, Aaron B. Cohen
Publikováno v:
Journal of Clinical Oncology. 39:7048-7048
7048 Background: Castleman disease (CD) has three subtypes: Unicentric (UCD), Human herpesvirus-8 associated multicentric (HHV-8 MCD) and idiopathic multicentric (iMCD). Outcomes for patients with iMCD are poor and treatment options are limited, with
Autor:
Stephen Zamora, José Ramón Cossío
Publikováno v:
International Journal of Constitutional Law. 4:411-437
This article discusses the fundamental changes that have occurred during the past decade in institutions central to Mexico’s constitutional order. The demise of a single-party democracy not only created a new political order; it generated, as well,
Autor:
Stephen Zamora
Publikováno v:
Proceedings of the ASIL Annual Meeting. 86:201-204
Publikováno v:
Proceedings of the ASIL Annual Meeting. 86:282-286
Autor:
Alexia Iasonos, Gary A. Ulaner, Michael F. Berger, Alex Morozov, Stephen Zamora, Teresa Gilewski, José Baselga, Mary Ellen Moynahan, Valentina Sterlin, Christina Coughlin, Nancy Sklarin, Sarat Chandarlapaty, Monica Fornier, Shanu Modi, Maura N. Dickler, Clifford A. Hudis, Joy Ero, Neal Rosen, Payal Deepak Shah
Publikováno v:
Journal of Clinical Oncology. 33:590-590
590 Background: HER2+ breast cancer is driven by HER2/HER3/PI3K signaling. Single agent targeted therapy (tx) is limited by redundant mechanisms of pathway activation and feedback loops; preclinica...
Autor:
Stephen Zamora, Mary Ellen Moynahan, Valentina Sterlin, Sarat Chandarlapaty, Shanu Modi, Gary A. Ulaner, Payal Deepak Shah, Maura N. Dickler, Clifford A. Hudis, José Baselga, Alexia Iasonos
Publikováno v:
Cancer Research. 75:OT3-1
Background: Breast cancers that overexpress the human epidermal growth factor receptor 2 (HER2+) are driven by HER2/HER3/PI3K signaling. Single agent therapy against this pathway is only modestly effective due to redundant mechanisms of pathway activ
Publikováno v:
Mexican Law
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d6fe0b3cb0b5ed0c8ceea1db7c5b6f63
https://doi.org/10.1093/acprof:oso/9780199288489.003.0005
https://doi.org/10.1093/acprof:oso/9780199288489.003.0005